Skip to content

Investigational Study to Evaluate the DPP® Syphilis Screen & Confirm Antibody Point-of-care Test (POCT) to Diagnose Infectious Syphilis

A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the DPP® Syphilis Screen & Confirm Antibody Point-of-care Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Nine Circles Community Health Centre in Winnipeg, Manitoba

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06927843
Enrollment
600
Registered
2025-04-15
Start date
2025-03-05
Completion date
2026-12-31
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Keywords

syphilis, Point of Care Test, Serology

Brief summary

The goal of this observational study is to evaluate the sensitivity, specificity, and utility of the DPP® Syphilis Screen & Confirm antibody point-of-care test (POCT) to diagnose infectious syphilis in participants attending the Nine Circles Community Health Centre in Winnipeg, Manitoba. The main questions are: Does the POCT provide accurate results compared to conventional syphilis serology methods? and Can the use of POCT improve the timeline for diagnosis and treatment of syphilis? Researchers will compare the POCT results with conventional laboratory testing to assess if the rapid test can reliably diagnose syphilis during the initial clinic visit. Participants will: Provide a blood sample via fingerstick for POCT testing and complete a feedback survey to evaluate the POCT experience. Key details: This study will involve approximately 600 participants aged 18 and older over the course of 12 months which includes both new and repeat visits

Interventions

DPP Syphilis Screen and Confirm antibody point-of-care-test (POCT)

Sponsors

University of Manitoba
Lead SponsorOTHER
Public Health Agency of Canada (PHAC)
CollaboratorOTHER_GOV
Chembio Diagnostic Systems, Inc.
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals attending the Clinic for routine sexual health care and requiring syphilis testing as part of this care * Be able to provide informed consent and are a minimum 18 years of age are eligible for this study * Those who had other STIs in the past, or being suspected of having other STIs, are not excluded as long as testing for syphilis is part of the care provided to them

Exclusion criteria

* Those who, at the discretion of the HCP/Research Nurse, appear intoxicated and/or with extreme distress, or confused, will be excluded * Those below the age of 18 years * if it has been less than 90 days since their last POCT study visit and they are asymptomatic.

Design outcomes

Primary

MeasureTime frameDescription
Point of Care Test PerformanceFrom start of enrollment to the end of the enrollment period (12 months)Sensitivity of POCT: Percentage of participants with laboratory-confirmed active syphilis who are identified as positive by the POCT, Specificity of POCT: Percentage of participants without laboratory-confirmed active syphilis who are identified as negative by the POCT

Secondary

MeasureTime frameDescription
Secondary POCT Performance MeasuresFrom start of enrollment to the end of the enrollment period (12 months)False Positive Rate: Percentage of participants without active syphilis who test positive by POCT for active syphilis. False Negative Rate: Percentage of participants with active syphilis who test negative by POCT for active syphilis.
Comparison of Results by POCT MethodologyFrom start of enrollment to the end of the enrollment period (12 months)Comparison of visual vs micro-reader assisted results

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORPrincipal Investigator

University of Manitoba

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026